Inhibrx Biosciences, Inc. INBX

INBX Company Overview

Inhibrx Biosciences, Inc. (NASDAQ: INBX) is a clinical-stage biotechnology company focused on the discovery and development of biologic therapeutics for oncology and rare diseases. The company develops engineered protein therapeutics and antibody-based drug candidates designed to target difficult-to-treat cancers and severe genetic or metabolic disorders. Following a major corporate restructuring completed in 2024, the company became primarily focused on advancing its rare disease pipeline, while certain oncology assets and related operations were transferred to a separate entity through a strategic transaction involving Sanofi.

The company’s principal value drivers are its proprietary biologic platforms and its clinical-stage therapeutic candidates, particularly programs targeting alpha-1 antitrypsin deficiency (AATD) and related conditions. Inhibrx originated as a biotechnology platform company leveraging advanced protein engineering technologies to develop multivalent and multispecific therapeutic candidates. Its evolution has included oncology immunotherapy development, strategic licensing transactions, and portfolio rationalization intended to concentrate resources on high-priority rare disease opportunities.